Day Laboratory

Our laboratory is interested in the role of oxidative stress in lung disease and antioxidant adaptive responses that the lung uses to prevent oxidative stress. In this regard, we are focused on lung thiols and their roles in preventing oxidative injury and in modulating inflammatory host defense responses. We also have active programs developing pharmacological approaches that either supplement antioxidant capacity or stimulate endogenous pathways to increase antioxidant capacity in the lung. Major lung diseases we are currently working on include chronic beryllium disease, chronic obstructive pulmonary disease, acute respiratory distress syndrome, cystic fibrosis, idiopathic pulmonary fibrosis and lung cancer.

Lab Resources and Services

Dr. Brian Day’s laboratory is located on the 4th floor of the Smith building on National Jewish Health’s campus. Learn more.

Current Projects

• Targeting oxidative stress in chronic beryllium disease.
• Adaptive glutathione responses to cigarette smoke in COPD.
• Developing novel antioxidant therapeutics for sulfur mustard toxicity.
• Role of thiols in host defense and oxidative stress in cystic fibrosis lung disease.
• Harnessing drug resistance and thiol efflux to treat cancer.

Personnel

• Principal Investigator
  Brian Day, PhD
• Professional Research Assistants
  Jie Huang, Elysia Min

• Graduate Students
  Joshua Chandler, Cameron McElroy

Collaborators

Publications

Gould, N.S., Min, E., Gauthier, S., Chu, H.W., Martin, R., and Day, B.J. Aging adversely affects the cigarette smoke induced glutathione adaptive response in the lung. Am. J. Respir. Crit. Care Med.182:1114-1122, 2010. Abstract

Dobis, D.R., Sawyer, R.T., Gillespie, M.M, Newman, L., Maier, L.A., and Day, B.J. Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production. Am. J. Respir. Cell Mol. Biol. 43:458-464, 2010. Abstract

More Publications